메뉴 건너뛰기
Annals of Oncology
Volumn 19, Issue 3, 2008, Pages 596-597
Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer [2]
Author keywords

[No Author keywords available]
Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAMOXIFEN; TRASTUZUMAB;
EID: 40149087502     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn021     Document Type: Letter
Times cited : (14)
References (8)
  • 1
    • 34347395733 scopus 로고    scopus 로고
    • Trastuzumab—mechanism of action and use in clinical practice
    • C.A. Hudis Trastuzumab—mechanism of action and use in clinical practice N Engl J Med 357 2007 39 51
    • (2007) N Engl J Med , vol.357 , pp. 39-51
    • Hudis, C.A.1
  • 2
    • 0035990831 scopus 로고    scopus 로고
    • Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
    • D. Gancberg A. Di Leo F. Cardoso Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites Ann Oncol 13 2002 1036 1043
    • (2002) Ann Oncol , vol.13 , pp. 1036-1043
    • Gancberg, D.1    Di Leo, A.2    Cardoso, F.3
  • 3
    • 33847165329 scopus 로고    scopus 로고
    • Intratumoral heterogeneity of HER2/neu in breast cancer—a rare event
    • W. Hanna S. Nofech-Mozes H.J. Kahn Intratumoral heterogeneity of HER2/neu in breast cancer—a rare event Breast J 13 2007 122 129
    • (2007) Breast J , vol.13 , pp. 122-129
    • Hanna, W.1    Nofech-Mozes, S.2    Kahn, H.J.3
  • 4
    • 0037089578 scopus 로고    scopus 로고
    • HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process
    • A. Vincent-Salomon M. Jouve P. Genin HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2002 2169 2173
    • (2002) Cancer , vol.94 , pp. 2169-2173
    • Vincent-Salomon, A.1    Jouve, M.2    Genin, P.3
  • 5
    • 0347539778 scopus 로고    scopus 로고
    • Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study
    • A. Vincent-Salomon G. MacGrogan J. Couturier Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study Histopathology 42 2003 337 347
    • (2003) Histopathology , vol.42 , pp. 337-347
    • Vincent-Salomon, A.1    MacGrogan, G.2    Couturier, J.3
  • 6
    • 1542720302 scopus 로고    scopus 로고
    • A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel
    • K. Kunitomo S. Inoue F. Ichihara A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel Hum Pathol 35 2004 379 381
    • (2004) Hum Pathol , vol.35 , pp. 379-381
    • Kunitomo, K.1    Inoue, S.2    Ichihara, F.3
  • 7
    • 85120100521 scopus 로고    scopus 로고
    • National Cancer Institute (France) NIH: Clinical Trials: Trastuzumab for 6 Months or 1 Year in Treating Women with Nonmetastatic Breast Cancer That Can Be Removed by Surgery. http://clinicaltrials.gov/show/NCT00381901 (25 January 2008, date last accessed)
  • 8
    • 33947587075 scopus 로고    scopus 로고
    • Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab?
    • B.E. Hillner T.J. Smith Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 25 2007 611 613
    • (2007) J Clin Oncol , vol.25 , pp. 611-613
    • Hillner, B.E.1    Smith, T.J.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.